Form 4: BIO-TECHNE CFO Reports Stock Transaction
Insider Transaction (Form 4)
James Hippel, CFO of BIO-TECHNE Corp, reported multiple transactions in common stock on July 29, 2026.
Summary
- Option exercise/conversion: acquired 62,068 Common Stock at $47.60 ($2,954,437) on July 29, 2026; holds 215,738 after (Direct).
- Tax/exercise-price withholding: disposed of 51,024 Common Stock at $72.03 ($3,675,259) on July 29, 2026; holds 164,714 after (Direct).
- Option exercise/conversion: disposed of 62,068 Stock Options (Right to Buy) on July 29, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
James Hippel — Officer (CFO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-29 | Option exercise/conversion | Common Stock | 62,068 | $48 | $3.0M | 215,738 |
| 2026-07-29 | Tax/exercise-price withholding | Common Stock | 51,024 | $72 | $3.7M | 164,714 |
| 2026-07-29 | Option exercise/conversion | Stock Options (Right to Buy) | 62,068 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-29 | Option exercise/conversion (62,068 shares) |
| 2026-07-29 | Tax/exercise-price withholding (51,024 shares) |
| 2026-07-29 | Option exercise/conversion (62,068 shares) |
Keywords
insider transaction, Form 4, TECH, BIO-TECHNE Corp, neutral, James Hippel
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.